Enliven Therapeutics, Inc. (ELVN)
USD 16.5
(2.68%)
USD 16.5
(2.68%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | 297 Thousand | 622 Thousand | 99 Thousand | 97 Thousand | 33 Thousand | - |
| Gross Profit | -297 Thousand | -622 Thousand | -99 Thousand | -97 Thousand | -33 Thousand | - |
| Operating Expenses | 83.52 Million | 38.79 Million | 24.76 Million | 9.31 Million | 24.08 Million | 10.67 Million |
| Selling, General and Administrative Expenses | 18.95 Million | 7.76 Million | 4.28 Million | 1.07 Million | 5.07 Million | 2.43 Million |
| Research and Development Expenses | 64.57 Million | 31.02 Million | 20.47 Million | 8.24 Million | 19 Million | 8.23 Million |
| Other Expenses | - | - | - | -9.67 Million | - | - |
| Cost and Expenses | 83.52 Million | 38.79 Million | 24.76 Million | 9.31 Million | 24.11 Million | 10.67 Million |
| Operating Income | -83.52 Million | -38.79 Million | -24.76 Million | -9.31 Million | -24.11 Million | -10.67 Million |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | - | 88 Thousand | -22 Thousand | -31 Thousand | 653 Thousand | -821.14 Thousand |
| Earnings before Tax | -71.58 Million | -37.66 Million | -24.74 Million | -18.96 Million | -23.46 Million | -11.33 Million |
| Net Income | -71.58 Million | -37.75 Million | -24.71 Million | -18.93 Million | -23.46 Million | -11.33 Million |
| Earnings Per Share Basic | -2.01 | -6.03 | -3.17 | -14.14 | -5.43 | -2.62 |
| Earnings Per Share Diluted | -2.01 | -6.03 | -3.17 | -14.14 | -5.43 | -2.62 |
| Weighted Average Shares Outstanding | 35.54 Million | 6.24 Million | 7.81 Million | 3.48 Million | 4.32 Million | 4.32 Million |
| Weighted Average Shares Outstanding (Diluted) | 35.54 Million | 6.24 Million | 7.81 Million | 3.48 Million | 4.32 Million | 4.32 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -81.93 Million | -38.57 Million | -24.64 Million | -9.27 Million | -23.43 Million | -11.33 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 440 Thousand | - | - | - |
| Cost of Revenue | 79 Thousand | 79 Thousand | 77 Thousand | 297 Thousand | 79 Thousand | 74 Thousand |
| Gross Profit | -79 Thousand | -79 Thousand | 363 Thousand | -297 Thousand | -79 Thousand | -74 Thousand |
| Operating Expenses | 24.52 Million | 25.9 Million | 22.65 Million | 83.23 Million | 24.24 Million | 20.13 Million |
| Selling, General and Administrative Expenses | 5.77 Million | 6.01 Million | 4.82 Million | - | 4.64 Million | 4.95 Million |
| Research and Development Expenses | 18.74 Million | 19.89 Million | 17.82 Million | - | 19.6 Million | 15.18 Million |
| Other Expenses | -1000.00 | -1000.00 | -9000.00 | - | -13 Thousand | - |
| Cost and Expenses | 24.6 Million | 25.98 Million | 22.72 Million | 83.52 Million | 24.24 Million | 20.13 Million |
| Operating Income | -24.6 Million | -25.98 Million | -22.72 Million | -83.52 Million | -24.24 Million | -20.13 Million |
| Interest Expense | - | - | 1.69 Million | - | - | - |
| Income Tax Expense | 232 Thousand | 35.72 Thousand | 5.18 Million | - | -3.49 Million | -48.08 Thousand |
| Earnings before Tax | -19.71 Million | -22.73 Million | -19.37 Million | -71.58 Million | -20.76 Million | -16.72 Million |
| Net Income | -19.95 Million | -22.73 Million | -19.37 Million | -71.58 Million | -20.76 Million | -16.72 Million |
| Earnings Per Share Basic | -0.41 | -0.54 | -0.47 | - | -0.51 | -0.41 |
| Earnings Per Share Diluted | -0.41 | -0.54 | -0.47 | - | -0.51 | -0.41 |
| Weighted Average Shares Outstanding | 48.07 Million | 42.04 Million | 41.12 Million | 35.54 Million | 41.03 Million | 40.96 Million |
| Weighted Average Shares Outstanding (Diluted) | 48.07 Million | 42.04 Million | 41.12 Million | 35.54 Million | 41.03 Million | 40.96 Million |
| Gross Margin | - | - | 0.82 | - | - | - |
| EBIT Margin | - | - | -51.48 | - | - | - |
| Profit Margin | - | - | -44.02 | - | - | - |
| EBITDA | -24.52 Million | -25.9 Million | -22.65 Million | - | -24.17 Million | -20.06 Million |
| Earnings Before Tax Margin | - | - | -51.66 | - | - | - |
NQMLF
BBROOM
4958
002961
OFX
SAM